Search Results - "Z.A. Wainberg"

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer by Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang

“…Background: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in…”
Get full text

Interim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC) by Wainberg, Z.A, George, B, Goldman, J.W, Hochster, H.S, Kelly, K, Ko, A, O'Dwyer, P.J, Trunova, N, Waterhouse, D, Soliman, H.H

“…Background: Combining a taxane with an immune checkpoint inhibitor has demonstrated improved responses across multiple tumors. Results from the Part 1 portion…”
Get full text

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies by Wainberg, Z.A, Hecht, J.R, Konecny, G.E, Chmielowski, B, Finn, R.S, Martinez, D, Yonemoto, L, Glaspy, J, Slamon, D.J

Get full text

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study by Subbiah, V., Kreitman, R.J., Wainberg, Z.A., Cho, J.Y., Schellens, J.H.M., Soria, J.C., Wen, P.Y., Zielinski, C.C., Cabanillas, M.E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., Keam, B.

“…Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on…”
Get full text

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics by Britten, C.D, Adjei, A.A, Millham, R, Houk, B, Wainberg, Z.A, Guthrie, T, Dy, G, LoRusso, P.M

Get full text

75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 by Wainberg, Z.A., Enzinger, P.C., Qin, S., Yamaguchi, K., Gnanasakthy, A., Taylor, K., Jamotte, A., Majer, I., Kang, Y-K.

Get full text

1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 by Wainberg, Z.A., Enzinger, P.C., Qin, S., Yamaguchi, K., Gnanasakthy, A., Jamotte, A., Majer, I., Kang, Y-K.

Get full text

1526P Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1 by Wainberg, Z.A., Yamaguchi, K., Ajani, J.A., Chao, J., Moehler, M., Kang, Y-K., Van Cutsem, E., Yen, P., Motii, Y., Zhou, D., Murias Dos Santos, T., Shitara, K.

Get full text

Cancer-Specific Mortality of Right- Versus Left-Sided Colorectal Adenocarcinoma: A Surveillance, Epidemiology, and End Results Database Analysis by Wang, C., Wainberg, Z.A., Raldow, A., Lee, P.

Get full text

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial by Klempner, S.J., Chao, J., Uronis, H., Sirard, C., Kagey, M., Baum, J., Song, J., Wang, J., Sonbol, M.B., Wainberg, Z.A., Ajani, J.A.

Get full text

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial by Yoon, H.H., Bendell, J.C., Braiteh, F.S., Firdaus, I., Philip, P.A., Cohn, A.L., Lewis, N., Anderson, D.M., Arrowsmith, E., Schwartz, J.D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S.R., Wainberg, Z.A.

“…This phase II trial examined the addition of ramucirumab, a vascular endothelial growth factor receptor-2 monoclonal antibody, to mFOLFOX6 as front-line…”
Get full text

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors by Marron, T.U., Misleh, J.G., C. chen, Wainberg, Z.A., Powderly, J., Boccia, R., Gordon, M., Segar, J., Csiki, I., Schanzer, J.M., O'Toole, L., Huang, N., Seppa, J., Glenn, J., Klumpp, K., Spira, A.I.

Get full text

1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma by Bahleda, R., Wainberg, Z.A., Spreafico, A., Ma, B., Subbiah, V., Ribrag, V., Duca, M., Fan, Y.Y., Cheng, Y., Lai, C., De Braud, F.

Get full text

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen by Ku, G.Y., Di Bartolomeo, M., Smyth, E., Chau, I., Park, H., Siena, S., Lonardi, S., Wainberg, Z.A., Ajani, J.A., Chao, J., Barlaskar, F., Kawaguchi, Y., Qin, A., Singh, J., Meinhardt, G., Van Cutsem, E.

Get full text

129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study by Oh, D-Y., Janjigian, Y.Y., Al-Batran, S-E., Wainberg, Z.A., van Cutsem, E., Molena, D., Muro, K., Hyung, W.J., Wyrwicz, L.S., Omori, T., Moehler, M., Garrido, M., Cunha Sousa Oliveira, S., Liberman, M., Castro Oliden, V., Bilici, M., Kurland, J., Xynos, I., Mann, H., Tabernero, J.

Get full text

193P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9 by Dean, A., Bekaii-Saab, T., Boland, P.M., Dayyani, F., Mercade, T. Macarulla, Mody, K., Belanger, B., Maxwell, F., Moore, Y., Wang, T., Zhang, B., Wainberg, Z.A.

Get full text

191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study by Dean, A., Bekaii-Saab, T., Boland, P.M., Dayyani, F., Mercade, T. Macarulla, Mody, K., Belanger, B., Maxwell, F., Moore, Y., Thiagalingam, A., Wang, T., Zhang, B., Wainberg, Z.A.

Get full text

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study by Janjigian, Y.Y., Al-Batran, S-E., Wainberg, Z.A., Van Cutsem, E., Molena, D., Muro, K., Hyung, W.J., Wyrwicz, L.S., Oh, D-Y., Omori, T., Moehler, M., Garrido, M., Cunha Sousa Oliveira, S., Liberman, M., Castro Oliden, V., Bilici, M., Kurland, J.F., Xynos, I., Mann, H., Tabernero, J.

Get full text

1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial by Melisi, D., Macarulla, T., de la Fouchardiere, C., Pazo Cid, R.A., Chandana, S., Dean, A., Kiss, I., Lee, W., Goetze, T.O., Van Cutsem, E., Paulson, A.S., Bekaii-Saab, T., Pant, S., Hubner, R., Xiao, Z., Zhang, L., Benzaghou, F.M., O'Reilly, E.M., Wainberg, Z.A.

Get full text

1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC) by Tehfe, M., Lee, J., Rha, S.Y., Nakamura, Y., Tabernero, J., Shitara, K., Oh, D-Y., Eads, J., Marshall, J., Wainberg, Z.A., Lee, K-W., Kang, Y-K., Liao, C-Y., Oh, S.Y., Yeh, K-H., Richards, D., Ubowski, M.M., Zhao, K., Bhaumik, S., Strickler, J.H.

Get full text